An observational study in Implant Infection, Skeletal Sarcoma and Hip Arthritis, sponsored by Vastra Gotaland Region. Enrolling by invitation at 1 site in Sweden. Per ClinicalTrials.gov, last updated 2025-12-04.
Sponsored by Vastra Gotaland Region · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The aim of this observational study is to gain knowledge on the microbial and immunological factors behind implant-related infections in patients with skeletal sarcoma.
The main research question the project aims to answer is:
Patients with skeletal sarcoma planned for primary surgery (tumour resection and replacement with a megaprosthesis) will be sampled intraoperatively to obtain a cross-section bone tissue slice at the resection margin, three soft tissue biopsies and joint fluid (if possible). Patients who develop a peri-prosthetic joint infection after their primary surgery will be sampled in a similar manner during revision surgery.
An additional group of patients with periprosthetic joint infection of a hip or knee prosthesis due to osteoarthritis will be sampled during their revision surgery (bone biopsies, soft tissue biopsies and joint fluid, if possible).
Blood samples will be taken from all patients pre-operatively for extensive biochemical and cellular analyses.
Researchers will compare periprosthetic tissues before and after infection. Further, periprosthetic infected tissues in patients treated for skeletal sarcoma will be compared to periprosthetic infected tissues in patientens treated for osteoarthritis. This will be done to attempt to identify host and microbial mechanisms responsible for the increased infection rate in patients with a megaprosthesis due to skeletal sarcoma (infection incidence rate up to 30%) compared to patients with a hip or knee prosthesis due to osteoarthritis (infection incidence rate 1-2%).
In orthopaedic oncology, the risk and consequences of orthopaedic device related infections (ODRIs) are heightened as the patients often have compromised immune responses due to underlying disease, chemotherapy or radiation. The implants used may be weight-bearing to the extent that they are impossible to remove or exchange in case of infection, and thereby, in worst case, resulting in amputation or death. Compared to the 1-2% incidence of PJI in a non-oncological population with a total hip- or knee prosthesis, patients with a megaprosthesis due to skeletal sarcoma have an infection incidence of 3-25%. Patient-related factors, extensive and repeated surgery and large reconstructive implants likely account for the increased incidence.
To our knowledge no study has evaluated the role of microbiological factors such as the biofilm production and susceptibility in this population. Further, deficient immunological factors in these patients, such as defect neutrophil migration, cytokine expression and phagocyte respiratory burst, involved in the killing of microbes, may provide an environment favouring more virulent phenotypes. Fundamental knowledge on the role of biofilm in this population could add to the improvement in treatment planning and outcome.
Distinguishing causative pathogens from contaminants may be challenging, especially in polymicrobial infections. The addition of metagenomic diagnostics, still sparsely used in clinical practice, may improve sensitivities, but predictive accuracy is still an issue. Comparing the results of conventional microbiological culturing with metagenomic sequencing would be of interest to determine the accuracy of current diagnostic methods.
The present study is an exploratory project addressing the multifactorial nature of PJI focusing on microbial phenotype in patients with skeletal sarcoma. The role of host, microbe and implant factors will be investigated using a set of different methods and compared to cases och PJI in patients will a conventional hip- or knee prosthesis.
Pre-operative blood samples will be taken and samples of peri-prosthetic soft tissue, bone and joint fluid will be collected intra-operatively. Patients will be sampled during their primary operation with a megaprosthesis due to skeletal sarcoma and in case of postoperative PJI, they will be sampled in the same manner during their revision surgery. Patients undergoing a reoperation due to PJI in a conventional total hip- or knee prosthesis will also be sampled with blood, bone, soft tissue and joint fluid intraoperatively.
Descriptive comparisons between (i) periprosthetic tissues and PJI tissues before and after infection in orthopaedic oncology patients, and (ii) PJI tissues in orthopaedic oncology and conventional PJI patients, will be made in regard to the following parameters:
Role of the host:
Role of the pathogen:
488 studies on the registry are indexed under Osteosarcoma; 123 are open to participants now.
This study's planned enrollment of 40 is below the median of 100 across 99 observational studies indexed under Osteosarcoma.
Browse Osteosarcoma studies →Vastra Gotaland Region is the lead sponsor of 276 studies on the registry; 110 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Three groups of patients will be studied:
All patients will be recruited consecutively at the Sahlgrenska University Hospital.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients who receive a megaprosthesis as a primary procedure for skeletal sarcoma.
Patients with a periprosthetic joint infection after surgery with a megaprosthesis due to skeletal sarcoma.
Non-immuncompromised patients with periprosthetic joint infection following a primary total hip or knee replacement.
Difference in virulence properties in causative microbes in the two groups of PJI
A descriptive analysis of genotype will be conducted
Time frame: Sampling will occur intraoperatively, bacteria will be frozen, no time frame neccessary
Differences in periprosthetic tissues in the two PJI groups
Descriptive analysis of periprosthetic tissue using histological methods
Time frame: Sampling will occur intraoperatively, tissues will be preserved, no time frame neccessary
Differences in biofilm production ability between causative microbes in the two PJI groups
Biofilm production will be assesed and categorised into none/weak and moderate/strong
Time frame: Sampling will occur intraoperatively, bacteria will be frozen, no time frame neccessary
Plan to share: No — The main results will be presented at an aggregated level. In some cases, individual data may be presented (e.g. characteristics of a bacterial strain in relation to clinical outcome), but this information will be unidentified so that it cannot be deduced to the individual. All compiled personal data will be stored on a password-protected hospital server that only the research group has access to. No personal data will be reported in publications. The results of the study will be documented according to the study protocol and placed in a journal. Participants will be coded in a document together with the social security numbers. Information about the participants, their health and the code key will be collected at the Orthopaedic Clinic where it will be treated confidentially and securely for 10 years. The handling of the participants' information is regulated by the Personal Data Act (SFS 1998: 204).
No publications or documents are linked to this record.
Started Feb 2025 (actual). Primary completion is estimated for Jun 2027, 28 months after the start.
Of 41 observational studies under Osteosarcoma, half reached primary completion within 76 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 228. This study's planned 28 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.